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Introduction: Statistical analyses of data and making
sense of medical data have received much attention in the
medical literature, but nevertheless have caused confusion
among practitioners. Each researcher provides a different
method for comparing treatments. For example, when the
end point is binary, such as disease versus no disease, the
common measures are odds ratios, relative risk, relative
risk reduction, absolute risk reduction, and the number
needed to treat. The question faced by the practitioner is
then: Which one will help me in choosing the best treat-
ment for my patient?
Methods: The purpose of this paper is to illustrate, using
examples, how each measure is used, what it means, and
what are its advantages and disadvantages.
Results: Some pairs of measures present equivalent infor-
mation. Furthermore, it is shown that different measures
result in different impressions.
Conclusion: It is recommended that researchers report
both a relative and an absolute measure and present these
with appropriate conﬁdence intervals.
Keywords: odds ratio, risk reduction, number needed to
treat, medical decision making.
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ABSTRACT
Introduction
In recent years, the amount of available information
in medical literature has increased rapidly, and as
more studies are performed, the results have
become more easily accessible. Even patients in 
the Internet era are aware of current research. The
problem is how to judge the evidence in various
published studies and decide whether it justiﬁes
changing the existing treatment for a new one. “At
the mention of the term ‘statistics’, most physicians
react with a groan of confusion and annoyance.”
[1]
The main difﬁculty in the comparison of differ-
ent treatments lies in the fact that they are almost
never compared, in a preplanned study, against each
other. Instead, most studies compare the new treat-
ment with a placebo. Moreover, the end points of
the studies may differ, the initial severity of the
disease may be different, the studies look at differ-
ent subsets of patients who had previously been
exposed to different drugs, and the outcome crite-
ria may be different. These problems imply limita-
tions to any systematic review of placebo-controlled
trials designed for regulatory purposes [2]. Obvi-
ously, the best way to compare several treatments
is to design a study that will include all treatments
to be compared, but that is a hard task to accom-
plish for regulatory purposes.
In the past few years, the issue of integrating the
results of several independent studies has been the
topic of many articles. While some suggest using
only relative risk [3], or absolute risk reduction [4],
others advocate use of the number needed to treat
criteria [5,6], and some consider the odds ratio to
be the method of choice [2]. Obviously, the choice
of method is linked to the type of study and its
design. For retrospective studies and for cross-
sectional studies, in which the aim is to look at the
association rather than differences, the odds ratio is
recommended, while a relative risk or risk differ-
ence cannot be meaningfully calculated. Risk cal-
culations are only meaningful in follow-up studies.
Odds ratio is also used in case-control studies, in
which the relative risk cannot be estimated.
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Methods
In the present article, we are mainly concerned with
controlled studies. We will describe the different
measures of treatment effects along with their
advantages and disadvantages and summarize some
of the debates regarding which one is to be used, as
reported in the medical literature in recent years.
Because the choice of treatment depends on the
measure being used, it is important that the practi-
tioner and the patient understand the differences
between the measures. We hope that this under-
standing will help in choosing the proper measure
for the case and recommend that both a relative and
an absolute measure be reported to give a more
complete picture.
Common Measures
Absolute risk reduction. The basic and simplest
measure is the absolute risk reduction (ARR), also
called the risk difference. That is, as a result of using
the treatment, is the risk of an event reduced by 
a clinically meaningful amount? The calculation is
just the difference between the risk of an event in
the control group and the risk of an event in the
treated group.
The advantage of the estimated ARR is that it is
easy to compute, the conﬁdence interval obtained is
easy to interpret (and is readily available with stan-
dard statistical packages), it reﬂects both the under-
lying risk without treatment and the risk reduction
associated with treatment, and has a clear meaning,
which makes it appealing to the practitioner. A con-
ﬁdence interval that contains zero means that there
is no signiﬁcant difference between the treatment
and the placebo in terms of risk. One disadvantage
is that a difference in risk of ﬁxed size may have
greater importance when the risks are close to 0 or
1 than when they are near the middle of the range.
A difference between 0.010 and 0.001, when 
considering the risk that people suffer serious side
effects, is more noteworthy than the difference
between 0.410 and 0.401 [7].
Number needed to treat. A related measure, based
on the absolute risk reduction, is the number needed
to treat (NNT), which is deﬁned as the reciprocal
of the absolute risk reduction. The meaning of this
measure is the number of patients that need to be
treated, to get the desired outcome in one patient
who would not have beneﬁted otherwise. Also,
when the outcome is binary, the cost-effectiveness
ratio becomes the product of the incremental costs
and the NNT. A conﬁdence interval (CI) for NNT
can be obtained by inverting the upper and lower
conﬁdence limits of absolute risk reduction. The
NNT has both advantages and disadvantages that
are discussed in the medical literature. It can be
easily understood and used and “[ . . . ] should 
help us to make the best clinical decisions with 
our patients.” Elferink and Van Zwieten-Boot [6]
encourage the use of NNT and state that NNT
takes into account the absolute beneﬁt and is a
meaningful measure because it addresses both 
statistical and clinical signiﬁcance in a way that is
easily interpreted. It is worth noting that the numer-
ical value of NNT is a function of the disease, the
intervention, and the outcome [5]. A NNT of 10
when the outcome is very serious may be judged 
differently than a NNT of 5 for a milder outcome.
Therefore, it is only appropriate to compare NNTs
directly, when treatments for the same condition,
severity, and outcome are compared.
When there is no difference in risk between the
treatment and control, the absolute risk reduction
is zero and NNT is inﬁnite. Also, when the differ-
ence is not signiﬁcant, the CI for absolute risk
reduction will include zero. Because a CI for NNT
is obtained by taking reciprocals of the CI for ARR,
we may get an ARR of 0.1, with a 95% CI of -0.05
to 0.25, which yields a NNT of 10 and a 95% CI
of -20 to 4. There are two problems with this inter-
val. First, NNT should be positive, and second, 
the CI does not include the point estimator. NNT is
equal to 10 in this case [8], for which McQuay 
and Moore suggest using only point estimates [5].
However, it is not satisfactory for a CI to be 
presented only when the result is signiﬁcant [8]. 
The interpretation of a negative value for NNT is
as follows: if NNT patients are treated with the new
treatment, one fewer patient will beneﬁt than if they
were all treated with the control. When NNT is neg-
ative, it is called NNH—the number needed to
harm. As ARR approaches zero, it means that there
is almost no difference between the new treatment
and the control, and therefore, inﬁnitely many
patients need to be treated for one to get well, who
otherwise would not have. The problem of inter-
preting a CI such as (95% CI, -20 to 4) still exists,
because ARR of zero translates into NNT equal to
inﬁnity. One simple solution is to report two sepa-
rate intervals: NNH (20–•) and NNT (4–•).
Altman [8] proposes combining both intervals into
one statement: NNTH 20 to • to NNTB 4.
To overcome the disadvantages, it has been sug-
gested that NNT be accompanied by the control
group event rate to which they apply and the rela-
tive risk and CI from which they are derived [3].
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Newcombe [4] suggests that absolute risk reduction
is a more basic quantity, with much less potential
to be misunderstood and is preferable to the NNT,
because of the NNT’s singularity problem. He sug-
gests that NNT and its CI will be used in an alter-
native way, when the absolute risk reduction is well
away from zero.
Relative risk and relative risk reduction. The next
two popular measures are relative risk (RR) and rel-
ative risk reduction (RRR). The relative risk of a
treatment is the ratio of risks of the treated group
and the control group, also called the risk ratio. The
relative risk reduction is derived from the relative
risk by subtracting it from one, which is the same
as the ratio between the ARR and the risk in the
control group.
RR is easy to compute and interpret and is
included in standard statistical software. The CI is
calculated by exponentiating the lower and upper
limits of the CI for log(RR), which has the general
form
(1)
However, the simple method for calculating the
CI does not perform well [9], and better methods
such as EquivTest [10] and CIA [11] can be used,
although they are not yet widely available.
One disadvantage of RR is that its value can be
the same for very different clinical situations. For
example, a RR of 0.167 would be the outcome for
both of the following clinical situations: 1) when the
risks for the treated and control groups are 0.3 and
0.05, respectively; and for 2) a risk of 0.84 for the
treated group and of 0.14 for the control group. RR
is clear on a proportional scale, but has no real
meaning on an absolute scale. Therefore, it is gen-
erally more meaningful to use relative effect mea-
sures for summarizing the evidence and absolute
measures for application to a concrete clinical or
public health situation [12].
Odds ratio. Odds ratio (OR) is a common measure
of the size of an effect and may be reported in case-
control studies, cohort studies, or clinical trials. It
can also be used in retrospective studies and cross-
sectional studies, where the goal is to look at asso-
ciations rather than differences. The odds is the
natural measure of effect size in logistic regression
modeling and can be interpreted as the ratio
between the number of patients who fulﬁll the cri-
teria and the number who do not or the number of
events relative to the number of nonevents. The odds
CI RR SE RR= ( ) ± ¥ ( )( )log . log .1 96
ratio is the ratio between the odds of the treated
group and the odds of the control group. It can be
obtained, along with its conﬁdence interval, using
standard statistical software. Both odds and odds
ratios are dimensionless. An odds ratio less than 1
means that the odds have decreased, and similarly,
an OR greater than 1 means that the odds have
increased. It should be noted that ORs are hard to
comprehend [13] and are frequently interpreted as
a relative risk. Although the odds ratio is close to
the relative risk when the outcome is relatively
uncommon [12], there is a recognized problem that
odds ratios do not give a good approximation of the
relative risk when the initial risk is high [13,14]. Fur-
thermore, an odds ratio will always exaggerate the
size of the effect compared to a relative risk [15,16].
When the OR is less than 1, it is smaller than the
RR, and when it is greater than 1, the OR exceeds
the RR. However, the interpretation will not, 
generally, be inﬂuenced by this discrepancy, because
the discrepancy is large only for large positive or
negative effect size, in which case the qualitative
conclusion will remain unchanged.
It is worthwhile to note that RR and OR are
related as follows:
(2)
where n11 is the frequency of (yes, group 1); n21 is
the frequency of (yes, group 2); n22 is the frequency
of (no, group 2); and n12 is the frequency of (no,
group 1).
This formula explains why OR approximates 
RR well when n11 and n21, the frequencies of the
“yes” outcome, are small relative to n12 and n22,
respectively. This is known as the “rare outcome
assumption.”
The odds ratio is the only measure of association
directly estimated from a logistic model, without
requiring special assumptions and regardless of
whether the study design is follow-up, case-control,
or cross sectional [17]. Risks can be estimated only
in follow-up designs. In case-control and cross-
sectional designs, the OR is a ratio, which depends
on four probabilities as follows:
(3)
where E = 1 if the patient was exposed, E = 0 
otherwise, D = 1 if the patient has the disease, and
D = 0 otherwise. It is worthwhile to note that risk
cannot be estimated from a case-control and cross-
sectional studies because they require conditional
OR =
= =( ) = =( )
= =( ) = =( )
ˆ ˆ
ˆ ˆ ,
P E D P E D
P E D P E D
1 1 0 1
1 0 0 0
RR OR= + ( )( ) + ( )( )* ,1 21 22 1 11 12n n n n
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probabilities of the type Pˆ(D|E), which are not
available.
Results
Hypothetical Example
A hypothetical example, used in part by McQuay
and Moore [5], will be used to illustrate the differ-
ent measures accompanied by their CIs. The study
aims to compare the recurrence of migraine
headaches in a control group receiving placebo and
a treated group receiving a new antimigraine prepa-
ration. For the sake of illustration, we examine four
different possible outcomes for the control and
treatment groups, denoted by C1 and M1 for study
1, C2 and M2 for study 2, C3 and M3 for study 3,
and C4 and M4 for study 4. It is assumed that all
groups were of 1000 individuals.
At the end of the study, migraine recurred in
30% of control group C1 (risk, 0.3), 5% of treat-
ment group M1, 84% of control group C2, 14% of
treatment group M2, 10% of control C3, 1.7% of
treatment group M3, and in 95% and 70% for C4
and M4, respectively, as summarized in Table 1.
The measures used are absolute risk reduction with
95% CI, risk, number needed to treat with 95% CI,
relative risk with 95% CI, risk reduction, odds, and
odds ratio with 95% CI.
It can be seen that:
1. The ﬁrst three cases have the same relative risk
and relative risk reduction, while case 4 is sig-
niﬁcantly different. However, the absolute risk
reduction, NNT, and odds ratios are signiﬁcantly
different in the three cases studied. (For odds
ratios, case 2 is different from cases 1 and 3,
which are similar.)
2. Cases 1 and 4 have the same absolute risk reduc-
tion, NNT, and odds ratios, but very different
relative risk, relative risk reduction, and risk at
baseline.
Real Example
The following example [18] is a prospective study,
which compares the incidences of dyskinesia after
ropinirole (ROP) or levodopa (LD) in patients with
early Parkinson’s disease. The results show that 17
of 179 patients who took ropinirole and 23 of 89
who took levodopa developed dyskinesia. The data
are summarized in Table 2.
The risk of having dyskinesia among patients
who took LD is 23/89 = 0.258, whereas the risk 
of developing dyskinesia among patients who took
ROP is 17/179 = 0.095
Therefore, the absolute risk reduction is
The variance of ARR is given by
(4)
Therefore, a 95% conﬁdence interval for the dif-
ference in proportions is given by
where 1.96 is the upper percentile of 2.5, taken
from a standard normal table for 95% CIs.
The number needed to treat and its CI are
obtained from ARR and its CI by taking the recip-
rocals as NNT = 1/ARR = 1/0.163 = 6.13, and its
CI is given by (1/0.264 - 1/0.063) = (3.79 - 15.87).
The relative risk is 0.095/0.258 = 0.368
The conﬁdence interval is obtained as follows: a
CI for the log of RR is obtained, and the lower and
0 163 1 96 0 00263 0 0636 0 264. . . . . ,± ¥ = -( )
V ARR( ) = -( ) +
-( ) =
0 258 1 0 258 89
0 095 1 0 095 179 0 00263
. .
. . . .
ARR = - =0 258 0 095 0 163. . . .
Table 1 The basic measures and corresponding 95% CIs for four cases*
C1 M1 C2 M2 C3 M3 C4 M4
Event 300 50 840 140 100 17 950 700
No event 700 950 160 860 900 983 50 300
Risk of event 0.3 0.05 0.84 0.14 0.1 0.017 0.95 0.7
ARR 0.25 0.70 0.083 0.25
CI 0.217–0.283 0.656–0.744 0.062–0.104 0.217–0.283
NNT 4 1.43 12.05 4
CI 3.53–4.60 1.34–1.52 9.65–16.02 3.53–4.60
RR 0.167 0.167 0.17 0.74
CI 0.125–0.222 0.143–0.195 0.102–0.282 0.706–0.769
RRR 0.833 0.833 0.83 0.26
Odds 0.429 0.053 5.25 0.163 0.111 0.017 19 2.33
OR 8.14 0.123 32.25 0.031 6.42 0.156 8.15 0.123
CI 0.090–0.168 0.024–0.04 0.092–0.262 0.090–0.168
*Ci and Mi (i = 1, . . . 4) are the hypothetical control and treated groups, respectively.
Abbreviations:ARR, absolute risk reduction; NNT, number needed to treat.
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upper limits are transformed to obtain the desired
interval.
The variance of log(RR) is given by
Therefore, a 95% CI for log(RR) is given by
Exponentiating the lower and upper conﬁdence
limits provides the 95% CI for RR: (0.207–0.653).
The odds of having dyskinesia for LD patients is
23/66 = 0.348. The odds of having dyskinesia for
ROP patients is 17/162 = 0.105, and therefore the
odds ratio OR is 0.105/0.348 = 0.302.
The procedure for obtaining a conﬁdence inter-
val is as follows: a CI for the log of OR is obtained,
and the lower and upper limits are then transformed
to obtain the desired interval.
The variance of log(OR) is given by
Therefore, a 95% CI for log(OR) is given by
Exponentiating the lower and upper limits, we
obtain the 95% CI for OR as (0.151–0.602).
Because RR is clear in proportional scale, but has
no real meaning on an absolute scale, it might be
best to report both—to use a relative effect measure
for summarizing the evidence and an absolute
measure for applying it to a concrete clinical or
public health situation. For our example, all the sta-
tistics show that ROP is better at preventing dysk-
inesia. However, it is best to report that the risk
with LD is three times higher than the risk with
ROP and that, by using ROP, the risk of develop-
ing dyskinesia is reduced by 16%. These two pieces
of information complete the picture.
An interesting study reported by Malenka et al.
[19] tested whether a patient’s perception of beneﬁt
Log OR
 to 
( ) ± ¥
= - ± ¥
= - -( )
1 96 0 1236
1 198 1 96 0 35157
1 887 0 508
. .
. . .
. . .
V log . .OR( )( ) = + + +( ) =1 23 1 66 1 17 1 162 0 1236
Log
 to 
0 368 1 96 0 08551
1 5727 0 4265
. . .
. . .
( ) ± ¥
= - -( )
V log . .RR( )( ) = - + - =1 23 1 89 1 17 1 179 0 08551
is inﬂuenced by how the beneﬁt is presented—in rel-
ative or absolute terms. They found that the
framing of beneﬁt or risk in relative versus absolute
terms may have a major inﬂuence on patient 
preference. The medication whose beneﬁts were
expressed in relative terms was chosen by 56.8% of
patients, whereas 14.7% chose the medication
whose beneﬁt was expressed in absolute terms.
Conclusion
The discussion above and the hypothetical example
were aimed at showing that choice of treatment
depends on the measure being used. Therefore, it 
is important that the practitioner understands 
what the different measures really express and
which ones may be more appropriate for a speciﬁc
patient setting. For example, ARR and NNT are
absolute measures, whereas RR and RRR are rela-
tive measures. It is recommended that both a rela-
tive and an absolute measure be reported, to
portray a more complete picture.
The author thanks Dr Rivka Inzelberg whose valuable
comments helped improve this paper.
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